RxDoctor Payments DataLook up a doctor →

Melissa Johnson, MD

Medical Oncology · Nashville, TNNPI 1821269465

Payments from drug & device makers

$45,973,133in general payments, 2019–2025

Across 7,823 payments — averaging $5876.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$9.8M
  • Array Biopharma Inc$4M
  • Daiichi Sankyo Inc.$3.2M
  • Boehringer Ingelheim International GmbH$3.2M
  • Regeneron$2.9M
  • Mirati Therapeutics, Inc.$2.7M
  • plus $20M from 54 others
$62,829in research payments, 2019–2025

Across 70 payments — averaging $897.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$34K
  • Boehringer Ingelheim$9K
  • F. Hoffmann-la Roche AG$6K
  • Regeneron$6K
  • Sanofi$3K
  • Amgen$3K
  • plus $2K from 1 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer472$9,807,875
Array Biopharma Inc236$4,032,353
Daiichi Sankyo Inc.1,726$3,246,102
Boehringer Ingelheim International GmbH737$3,246,080
Regeneron511$2,876,798
Mirati Therapeutics, Inc.491$2,737,308
Genentech, Inc.389$2,649,106
Amgen93$2,203,886
Merck105$1,409,068
Daiichi Sankyo Company LTD116$1,290,888
E.r. Squibb & Sons, L.L.C.39$1,172,735
Novartis34$1,122,480
Janssen Research & Development, LLC210$1,093,591
Genmab U.S., Inc.111$974,484
Boehringer Ingelheim91$896,110
AstraZeneca85$864,097
Eli Lilly15$597,946
Exelixis Inc.338$561,910
F. Hoffmann-la Roche AG128$552,174
Takeda Pharmaceuticals U.S.A., Inc.158$551,978
Boehringer Ingelheim Pharma GmbH & Co.kg90$504,442
Incyte Corporation393$482,065
GSK265$398,175
AbbVie115$378,218
Astrazeneca UK Limited32$363,300
Genmab A/s116$347,581
Y-mabs Therapeutics, Inc.52$294,431
Sanofi US Services Inc.62$237,472
EMD Serono, Inc.190$211,049
Helsinn Healthcare SA55$188,082
Taiho Oncology, Inc.46$138,005
Beigene AUS Pty Ltd12$80,240
Verastem, Inc.12$69,389
Bristol Myers Squibb6$56,597
Beigene, Ltd.63$55,604
Puma Biotechnology, Inc.6$46,185
Kadmon Corporation LLC3$37,249
Dynavax Technologies Corporation17$37,206
Roche TCRC, Inc.11$33,850
Hoffmann-la Roche Limited7$28,740
Seagen Inc.19$26,125
Merck Healthcare Kgaa40$18,411
Janssen Global Services, LLC4$11,180
Jazz Pharmaceuticals Inc.4$6,691
Acerta Pharma LLC1$6,185
Johnson & Johnson11$4,873
Janssen Scientific Affairs, LLC3$4,195
Roche Molecular Systems, Inc.9$3,538
Gilead5$3,482
Genentech USA, Inc.11$3,412
Immunocore Limited1$2,800
Adaptimmune LLC2$2,700
Beone Medicines USA, Inc.2$2,430
Boehringer Ingelheim Espana S.A.13$987
Regeneron Healthcare Solutions, Inc.26$506
Astellas Pharma US Inc7$108
Novocure Inc.2$102
Sanofi3$88
Eisai Inc.4$85
Bayer3$59

How this compares

$45,973,133 in reported general payments places this provider in the 95th percentile of 101 medical oncology providers in Tennessee.

See all medical oncology providers in Tennessee →

Medicare billing

Part B allowed, 2024
$1,195,735
Medicare patients
234
Services billed
34,843

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Nashville

See the full list for Tennessee →

Where these figures come from

Is this you, or does something look wrong? →